Press Release: Claritev Appoints Jennifer Main to Its Board of Directors

Dow Jones
10/15

MCLEAN, Va., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data, and insights company, today announced that its Board of Directors ("Board") has appointed Jennifer (Jenni) Main as a director, effective today, filling a newly created directorship on the Board. Main brings more than three decades of leadership experience across healthcare, technology, government, and finance. She currently serves as Chief Financial Officer of RealMDai (dba Certuma) and Overture Life, roles she has held since March 2026. Previously, she served as Chief Financial Officer and Chief Operating Officer of Amalgam Rx from 2021 to 2026.

"Jenni brings a valuable combination of financial leadership, healthcare experience, and public sector perspective," said Travis Dalton, President and CEO of Claritev. "Her understanding of the healthcare ecosystem and experience leading through complex operating environments will be a strong asset to our Board as we continue to advance our strategy and deepen our impact across the industry."

Main previously held several leadership roles at the Centers for Medicare & Medicaid Services (CMS), most recently serving as its Chief Operating Officer from 2018 to 2021. In that role, she oversaw operational execution across the agency's Medicare, Medicaid, and federal health insurance marketplace program, gaining firsthand insight into the regulatory and operational challenges facing payers, providers, and government healthcare programs.

Main also served as Chief Financial Officer for the Troubled Assets Relief Program (TARP) at the U.S. Department of Treasury, where she led the development and implementation of financial management services for the $700 billion program established in response to the 2008 financial crisis. Main holds a master's degree in public policy from Harvard University and a bachelor's degree in history from Cornell University.

"I'm excited to join the Board at such a pivotal moment in the company's evolution," said Main. "Claritev operates at the intersection of payers, providers, employers, and government, and its mission to make healthcare more affordable and transparent strongly resonates with me. I look forward to working with the Board and management team to help Claritev deliver even greater value to its clients and the patients they ultimately serve."

About Claritev

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders -- including payers, employers, patients, providers, and third parties -- Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

Investor Relations Contacts

Todd Friedman

Head of Investor Relations and Strategic Communications

Claritev

investor@claritev.com

Media Relations Contact

Jen O'Connor

VP, Brand Marketing

Claritev

press@claritev.com

SOURCE: Claritev Corporation

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/099033e4-e76a-412a-9627-bc8a6778b00f

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10